Hims & Hers Health Inc. Aktie News

Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, the Novo Nordisk partnership breakup, and shifting GLP-1 compounding regulations impacting revenue and investor sentiment. HIMS's valuation sits between telehealth and AI/genomics peers, with substan...

Hims & Hers is down 50% from all-time highs amid fading momentum in their compounded GLP-1 offerings, while new growth vectors are yet to translate into revenue acceleration. Sequential revenue deceleration, margin contraction, and lowered FY25 guidance have pressured Hims stock, but management maintains ambitious 2030 targets. New growth vectors—testosterone, menopause, Labs, and international...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integration, and a unique personalized offering position HIMS to regain historical growth rates by 2026 and beyond. Management targets substantial margin expansion, aiming for adjusted EBITDA margins of at l...

Hims & Hers Health is aggressively expanding through new product launches, international markets, and strategic acquisitions, supporting a bullish outlook. HIMS targets $6.5 billion in 2030 revenue, leveraging a subscriber base with significant runway to reach a 10 million target. Management signals potential to exceed long-term targets, reinforced by a $250 million share buyback reflecting con...

Hims & Hers is an asset-light platform. Subscriptions, cross-selling, and personalization drive rising ARPU, strong retention, and improving unit economics with structurally low CAC. Growth has normalized but remains ~50%+, driven by weight loss, Hers, diagnostics, and international expansion. Focusing on personalized plans lifts ARPU and retention, improving revenue quality. Margin volatility ...

HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international expansion through M&A activities, and strong operating leverage underpin HIMS' long-term revenue and EBITDA growth prospects. Regulatory headwinds from the FDA and new legislation pose near-term risks, but...

Hims & Hers Health shares are down 30%, but I maintain a Buy rating due to compelling long-term growth levers. HIMS's core business growth is slowing, yet margin expansion, product innovation, and international expansion underpin mid-term shareholder value. GLP-1's legal clarity and new hormone care verticals—testosterone and menopause—offer strong upsell potential and improved retention.

Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into new specialties and diagnostics, with international growth representing a $1 billion medium-term opportunity. Q3 revenue grew 49% y/y to $599 million, beating expectations, with subscriber growth ...